Sacituzumab Govitecan and Pembrolizumab in Triple-Negative Breast Cancer
In this article
Treatment Standards in Triple-Negative Breast Cancer Are Changing: ASCENT-04 / KEYNOTE-D19 Published in NEJM
Metastatic triple-negative breast cancer (mTNBC) is one of oncology's most challenging settings because of its aggressive nature and limited treatment options. The full report of the long-awaited ASCENT-04 / KEYNOTE-D19 Phase 3 study has been published in the medical world's most prestigious journal, New England Journal of Medicine (NEJM). The results provide a strong answer to the question of whether we are entering a "chemotherapy-free" era in first-line treatment.
Study Summary: In patients with PD-L1-positive (CPS ≥10) metastatic TNBC, this study compared first-line standard chemotherapy (physician's choice) plus pembrolizumab with the antibody-drug conjugate (ADC) Sacituzumab Govitecan (SG) plus Pembrolizumab , demonstrating statistically and clinically significant improvements in both progression-free survival (PFS) and overall survival (OS).
HR: 0.65 (p<0.0001)
HR: 0.70
Deeper tumor shrinkage
More durable efficacy
Why This Combination? (Biological Rationale)
The mechanism highlighted in the NEJM article is based on the synergy of two powerful weapons:
- Sacituzumab Govitecan (SG): It targets the Trop-2 antigen, attaching to the tumor cell like a "guided missile" and releasing SN-38, a potent chemotherapy agent, inside the cell. It also kills nearby tumor cells through the "Bystander Effect."
- Pembrolizumab: By releasing the immune-system brake (PD-1), it enables T cells to attack tumor cells broken down by SG.
Difference in Progression-Free Survival (PFS)
Risk Reduction: 35%*Data are taken from the NEJM publication. The 35% reduction in the risk of disease progression or death is statistically significant.
What Changes in Clinical Practice?
This study strongly demonstrates that, in first-line treatment for patients with PD-L1-positive mTNBC, SG could replace standard chemotherapy (paclitaxel, gemcitabine, etc.) . In particular, median overall survival exceeding 2 years (24.2 months) is a historic achievement for this patient group.
Patient Selection and Safety
Patients in the study had received no prior treatment for metastatic disease and had a PD-L1 CPS score ≥10.
Adverse-Effect Management
The most common adverse effects in the SG arm were neutropenia (low white blood cell count) and diarrhea. However, the article stated that these effects were manageable with dose adjustments and supportive care, and that treatment-related deaths were low and similar in both arms.
Tumor Response Rates
Tumor shrinkage was achieved in approximately 7 of every 10 patients.
Commentary from Prof. Dr. Mustafa Özdoğan
"This study published in NEJM marks the breakthrough we have long awaited in triple-negative breast cancer. By extending survival while preserving quality of life compared with chemotherapy, this combination is on its way to becoming the new standard for eligible patients (high PD-L1). We now have smarter weapons that target tumor biology rather than merely suppressing the tumor."
Source: The New England Journal of Medicine, 2026. "Sacituzumab Govitecan plus Pembrolizumab in First-Line Metastatic TNBC (ASCENT-04)". This content is for informational purposes; consult your physician about treatment decisions.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.